About Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SRPT
CUSIPN/A
Phone617-274-4000
Debt
Debt-to-Equity Ratio0.54%
Current Ratio13.91%
Quick Ratio12.96%
Price-To-Earnings
Trailing P/E Ratio-49.37
Forward P/E Ratio-65.46
P/E GrowthN/A
Sales & Book Value
Annual Sales$154.58 million
Price / Sales32.75
Cash FlowN/A
Price / CashN/A
Book Value$12.21 per share
Price / Book6.38
Profitability
EPS (Most Recent Fiscal Year)($1.64)
Net Income$-50,680,000.00
Net Margins-32.79%
Return on Equity-30.59%
Return on Assets-22.85%
Miscellaneous
Employees255
Outstanding Shares64,980,000
Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions
What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
How were Sarepta Therapeutics' earnings last quarter?
Sarepta Therapeutics Inc (NASDAQ:SRPT) posted its quarterly earnings results on Thursday, March, 1st. The biotechnology company reported ($0.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.32) by $0.05. The biotechnology company had revenue of $57.30 million for the quarter, compared to analysts' expectations of $57.33 million. Sarepta Therapeutics had a negative net margin of 32.79% and a negative return on equity of 30.59%. The company's quarterly revenue was up 961.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.71) EPS. View Sarepta Therapeutics' Earnings History.
When is Sarepta Therapeutics' next earnings date?
What price target have analysts set for SRPT?
19 equities research analysts have issued twelve-month price objectives for Sarepta Therapeutics' stock. Their forecasts range from $55.00 to $101.00. On average, they expect Sarepta Therapeutics' share price to reach $82.5906 in the next year. View Analyst Ratings for Sarepta Therapeutics.
What are Wall Street analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- 1. According to Zacks Investment Research, "Sarepta's Exondys 51 is the first DMD treatment to gain approval in the United States. Also, a potential marketing approval in the EU should further boost sales.The company is also focused on reimbursement programs. Moreover, the company’s collaboration agreements with Summit Pharmaceuticals and Catabasis as well as its own follow-on exon-skipping pipeline candidates represent the most comprehensive approach to treat DMD. Meanwhile, the settlement of the patent litigation with BioMarin removes a major overhang for Sarepta. However, dependence on a single product, Exondys 51, is a concern. Nonetheless, Sarepta expects a pickup in patient starts and conversion rates as 2017 progresses. The company’s shares have outperformed the industry so far this year. Loss estimates have remained stable ahead of Q4 earnings. The company has a mixed record of earnings surprises in the recent quarters." (2/7/2018)
- 2. Cowen Inc analysts commented, "SRPT reported 1Q17 results, including a slight Exondys 51 beat and raise; we see." (4/28/2017)
Who are some of Sarepta Therapeutics' key competitors?
Some companies that are related to Sarepta Therapeutics include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), BeiGene (BGNE), SAGE Therapeutics (SAGE), Alkermes (ALKS), Valeant Pharmaceuticals International (VRX), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr. Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Gal�pagos (GLPG), United Therapeutics (UTHR), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), Blueprint Medicines (BPMC) and GW Pharmaceuticals (GWPH).
Who are Sarepta Therapeutics' key executives?
Sarepta Therapeutics' management team includes the folowing people:
- Douglas S. Ingram, President, Chief Executive Officer (Age 54)
- Sandesh Mahatme, Executive Vice President, Chief Financial Officer and Chief Business Officer (Age 52)
- David Tyronne Howton Jr., Senior Vice President, General Counsel, Corporate Secretary (Age 45)
- Alexander Cumbo, Senior Vice President, Global Commercial Development (Age 46)
- Shamim Ruff, Senior Vice President - Regulatory Affairs and Quality (Age 57)
- Catherine Stehman-Breen M.D., Senior Vice President, Chief Medical Officer (Age 54)
- Michael W. Bonney, Director (Age 59)
- Richard J. Barry, Independent Director (Age 58)
- M. Kathleen Behrens Ph.D., Independent Director (Age 64)
- Claude Nicaise M.D., Independent Director (Age 64)
Has Sarepta Therapeutics been receiving favorable news coverage?
Headlines about SRPT stock have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sarepta Therapeutics earned a coverage optimism score of 0.22 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Sarepta Therapeutics?
Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sarepta Therapeutics' stock price today?
One share of SRPT stock can currently be purchased for approximately $78.43.
How big of a company is Sarepta Therapeutics?
Sarepta Therapeutics has a market capitalization of $5.19 billion and generates $154.58 million in revenue each year. The biotechnology company earns $-50,680,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Sarepta Therapeutics employs 255 workers across the globe.
How can I contact Sarepta Therapeutics?
Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected]
MarketBeat Community Rating for Sarepta Therapeutics (SRPT)
MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote "Outperform" if you believe SRPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Sarepta Therapeutics (NASDAQ:SRPT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
19 Wall Street analysts have issued ratings and price targets for Sarepta Therapeutics in the last 12 months. Their average twelve-month price target is $82.5906, suggesting that the stock has a possible upside of 6.02%. The high price target for SRPT is $101.00 and the low price target for SRPT is $55.00. There are currently 2 hold ratings and 17 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.89 | 2.90 | 2.85 | 2.80 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $82.5906 | $78.4542 | $66.2755 | $65.7895 |
| Price Target Upside: | 6.02% upside | 3.41% downside | 7.17% upside | 29.66% upside |
Sarepta Therapeutics (NASDAQ:SRPT) Consensus Price Target History
Sarepta Therapeutics (NASDAQ:SRPT) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Sarepta Therapeutics (NASDAQ:SRPT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Sarepta Therapeutics (NASDAQ SRPT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 84.98%
Sarepta Therapeutics (NASDAQ SRPT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/30/2017 | Hans Lennart Rudolf Wigzell | Director | Sell | 6,667 | $55.89 | $372,618.63 | 13,333 |  |
| 11/8/2017 | Douglas S Ingram | CEO | Buy | 38,138 | $52.44 | $1,999,956.72 | 420,196 | |
| 11/6/2017 | Shamim Ruff | SVP | Sell | 10,000 | $55.00 | $550,000.00 | 37,045 | |
| 10/3/2017 | Shamim Ruff | SVP | Sell | 11,500 | $50.00 | $575,000.00 | | |
| 7/27/2017 | Douglas S Ingram | CEO | Buy | 47,058 | $42.50 | $1,999,965.00 | 382,058 | |
| 7/21/2017 | Shamim Ruff | SVP | Sell | 12,138 | $42.97 | $521,569.86 | 27,312 | |
| 7/20/2017 | Alexander Cumbo | SVP | Sell | 5,918 | $41.00 | $242,638.00 | 22,793 | |
| 7/20/2017 | Edward M Md Kaye | Director | Sell | 10,000 | $41.00 | $410,000.00 | 62,471 | |
| 7/20/2017 | Sandesh Mahatme | CFO | Sell | 50,000 | $41.00 | $2,050,000.00 | 41,736 | |
| 10/17/2016 | Sandesh Mahatme | Insider | Sell | 30,000 | $50.08 | $1,502,400.00 | 61,532 | |
| 9/22/2016 | David T Howton | SVP | Sell | 7,000 | $60.00 | $420,000.00 | 28,453 | |
| 9/22/2016 | Edward M Md Kaye | CEO | Sell | 40,179 | $60.00 | $2,410,740.00 | 117,162 | |
| 9/19/2016 | David T Howton | SVP | Sell | 9,304 | $50.00 | $465,200.00 | 11,168 | |
| 9/19/2016 | Edward M Md Kaye | CEO | Sell | 24,352 | $50.00 | $1,217,600.00 | 89,983 | |
| 9/19/2016 | Jayant Aphale | VP | Sell | 35,000 | $50.00 | $1,750,000.00 | 21,490 | |
| 9/14/2016 | Edward M Md Kaye | CEO | Sell | 24,557 | $30.00 | $736,710.00 | 76,983 | |
| 3/16/2016 | M Kathleen Behrens | Director | Buy | 10,000 | $14.54 | $145,400.00 | 112,166 | |
| 3/14/2016 | M Kathleen Behrens | Director | Buy | 65,000 | $16.54 | $1,075,100.00 | 112,166 | |
| 11/14/2013 | Anthony Chase | Director | Buy | 10,000 | $13.95 | $139,500.00 | 41,744 | |
| 9/16/2013 | M Kathleen Behrens | Director | Buy | 6,500 | $37.04 | $240,760.00 | 44,166 | |
| 9/3/2013 | John Hodgman | Director | Sell | 5,556 | $34.97 | $194,293.32 | | |
| 8/22/2013 | Anthony Chase | Director | Buy | 3,500 | $32.68 | $114,380.00 | 31,744 | |
| 8/20/2013 | Sandesh Mahatme | CFO | Buy | 5,000 | $31.10 | $155,500.00 | 5,000 | |
| 6/14/2013 | Anthony R Chase | Director | Buy | 10,000 | $38.50 | $385,000.00 | | |
| 9/7/2012 | M Kathleen Behrens | Director | Buy | 17,500 | $14.73 | $257,775.00 | | |
(Data available from 1/1/2013 forward)
Sarepta Therapeutics (NASDAQ SRPT) News Headlines
| Source: |
|
Sarepta Therapeutics (NASDAQ:SRPT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Sarepta Therapeutics (NASDAQ:SRPT) Income Statement, Balance Sheet and Cash Flow Statement
Sarepta Therapeutics (NASDAQ SRPT) Stock Chart for Thursday, April, 19, 2018
Loading chart…
